MLL advised AFFiRiS on the sale of its IP portfolio to AC Immune

AFFiRiS biotechnology company has entered into a definitive agreement with AC Immune in regards to the sale of its entire portfolio of anti-alpha-synclein immunotherapies in exchange for shares in AC Immune with regard to all Swiss law aspects.

AFFiRiS is an Austrian biotechnology company developing vaccines for the treatment of neurodegenerative and cardiometabolic diseases such as Parkinson’s disease and hypercholesterolemia. AC Immune is a Swiss biopharmaceutical company.

The total value of the equity-based acquisition was USD 58.7 million. The transaction involved structuring an asset deal to transfer the assets from AFFiRiS to AC Immune, the subscription of shares in the listed AC Immune, and the financing of AFFiRiS by its shareholders. Under the terms of the transaction, AFFiRiS sold all of the assets and related intellectual property of AFFiRiS associated with its portfolio of anti-alpha-synclein immunotherapies.

AFFiRiS advisors

MLL advised AFFiRiS on all Swiss law aspects of the acquisition. The team was led by partner Andrea Sieber (corporate law, pictured) and consisted associate Philipp Falk (corporate law)

AFFiRiS was represented by Eisenberger & Herzog Attorneys-at-Law. The team consisted partner Marco Steiner and attorney c as lead counsel.

Ashurst partner Lloyd Harmetz advised AFFiRiS on all aspects of the U.S. laws.